NASDAQ$CABA

Cabaletta Bio Inc · Q4 2024 earnings

Q4 2024 earnings · · Before market open · Investor relations

Briefing

Cabaletta Bio reported Q4 2024 a net loss of $32.6M, diluted EPS of $-0.65.

For Q4 2024, Cabaletta Bio reported net loss was $32.6M, diluted EPS was $-0.65. Management discusses segment trends, liquidity, and outlook in the quarterly filing.

  • Net loss $32.6M.
  • Diluted EPS $-0.65.
  • MD&A highlights operating priorities, liquidity, and sector risks.

Headline financials

Total Revenue

$0.00

Previous: $4.01M-100.0%
EPS (adj)

-$0.65

Previous: -$0.46-41.3%
Research and Development Expenses

$97.2K

Previous: $55.4K+75.4%
General and Administrative Expenses

$27.9K

Previous: $19.2K+45.2%
Interest Income

$10K

Previous: $6.99K+43.5%
Interest Expense

$748.00

Previous: $0.00
Stock-Based Compensation

$19.5K

Previous: $11.3K+71.6%
Depreciation

$1.71K

Previous: $1.43K+20.0%
Non-Cash Operating Lease Expense

$2.84K

Previous: $2.07K+37.1%
Accretion of Operating Lease Liabilities

$405.00

Previous: $408.00-0.7%
Loss on Foreign Currency Exchange Rates

$38.00

Previous: $0.00
Prepaid Expenses and Other Current Assets

$528.00

Previous: -$954.00+155.3%
Other Assets

-$584.00

Previous: -$1.14K+49.0%
Accounts Payable

$1.01K

Previous: $1.68K-39.6%
Accrued and Other Current Liabilities

$3.95K

Previous: $2.98K+32.4%
Lease Liabilities

-$3.29K

Previous: -$2.46K-34.0%
Purchases of Property and Equipment

-$2.21K

Previous: -$687.00-221.8%
Principal Payments on Finance Leases

-$897.00

Previous: $0.00
Effect of Exchange Rate Changes on Cash and Cash Equivalents

-$20.00

Previous: $0.00
Net Decrease in Cash and Cash Equivalents

-$29.3K

Previous: $112K-126.2%
Cash Paid for Interest

$748.00

Previous: $0.00
Right-of-Use Assets from Finance Lease Obligations

$11K

Previous: $2.05K+435.3%
Net Income

-$32.6M

Previous: -$20.9M-56.0%
Operating Income

-$125K

Previous: -$23.1M+99.5%

Revenue & EPS history

Cabaletta Bio · Revenue · Quarterly

$0

Q4 2024-100%vs Q4 2023
Beat estimate in 0 of 1 quarters(0%)
ActualEstimate

Forward guidance

Outlook emphasizes milestones, liquidity runway, and cost discipline.

Tailwinds

  • Pipeline progress and partnership economics.
  • Cash supports near-term operating plans.

Headwinds

  • Operating losses until commercial scale.
  • Financing and competition affect funding costs.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 19 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

+2.7%

Avg return

Earnings day

+3.2%

Avg return

5 days after

+5.3%

Avg return

30 days after

67%

16 / 24 earnings

Positive

+22.7%

Q3 2022

Best reaction

-24.4%

Q3 2024

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2026-7.8%-9.0%-16.2%
Q3 2025-5.0%-9.4%-5.1%
Q1 2025-0.6%+6.9%-2.9%
Q4 2024+12.8%-28.4%-14.8%
Q3 2024-24.4%-36.7%-29.7%
Q1 2024+12.4%+14.7%-5.1%
Q4 2023-4.2%-6.4%-26.4%
Q3 2023+4.0%+1.6%-5.6%
Q2 2023+10.0%+10.4%+12.0%
Q1 2023+1.6%+7.0%-1.2%
Q4 2022+9.3%+4.3%+5.4%
Q3 2022+22.7%+84.0%+207.2%
Q2 2022+19.5%+17.2%-26.3%
Q1 2022+21.1%+52.8%-3.3%
Q4 2021+14.6%+32.7%+6.4%
Q3 2021+2.4%-5.3%-19.1%
Q2 2021+2.0%+1.9%+58.0%
Q1 2021-6.6%-14.0%-7.2%
Q4 2020+1.7%-4.0%-8.7%
Q3 2020+6.7%+7.1%+19.3%
Q2 2020+6.4%+4.6%-15.8%
Q1 2020-9.3%-8.0%-8.0%
Q4 2019+0.3%-7.6%+10.7%
Q3 2019-23.7%-38.7%+3.7%
Q2 2019
Q1 2019
Q4 2018
Q3 2018
Q2 2018
Q1 2018

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro